PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Interest in Shares

13 Jan 2015 15:28

RNS Number : 0633C
ReNeuron Group plc
13 January 2015
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

Reneuron Group

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation:

Invesco Limited

4. Full name of shareholder(s)  (if different from 3.):

5. Date of the transaction and date onwhich the threshold is crossed orreached:

12 January 2015

6. Date on which issuer notified:

13 January 2015

7. Threshold(s) that is/are crossed orreached:

5%

 

8. Notified details:

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

 

GB00B0DZML60

158,000,000

158,000,000

88,000,000

4.92%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date

Exercise/Conversion period

Number of voting rights instrument refers to

 

% of voting rights

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

88,000,000

4.92%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Invesco Fund Managers Limited = 88,000,000

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Philippa Sadler

15. Contact telephone number:

01491 417 000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLGGUAPGUPAGAW
Date   Source Headline
9th Oct 20177:00 amRNSPresentation of positive pre-clinical data
12th Sep 20177:00 amRNSDirectors' Interest in Shares and Share Options
6th Sep 201711:15 amRNSResult of AGM
6th Sep 20177:00 amRNSAGM Trading Update
1st Sep 20177:00 amRNSNon-executive Director Appointment
1st Sep 20177:00 amRNSBlock Listing Review and TVR
7th Aug 20173:04 pmRNSPosting of Annual Report and Notice of AGM
4th Aug 20174:40 pmRNSSecond Price Monitoring Extn
4th Aug 20174:35 pmRNSPrice Monitoring Extension
25th Jul 20177:00 amRNSAppointment of joint broker
19th Jul 20177:00 amRNSBoard change
29th Jun 20177:00 amRNSPreliminary Results
19th Jun 20177:00 amRNSFDA approves cryopreserved hRPC formulation
8th Jun 20177:00 amRNSNotification of Preliminary Results
5th Jun 20177:00 amRNSPositive FDA feedback on proposed Phase III study
18th May 20177:00 amRNSPresents positive exosome data at major conference
11th May 20177:00 amRNSAwarded major UK cell therapy manufacturing grant
5th May 20177:00 amRNSPresents new exosome data at major conference
21st Apr 20177:01 amRNSUpdate on clinical strategy in stroke disability
21st Apr 20177:00 amRNSUpdate on progress in ophthalmology programmes
1st Mar 20177:00 amRNSBlock Listing Review and Total Voting Rights
15th Feb 20177:00 amRNSReNeuron featured in BBC documentary
7th Feb 201712:32 pmRNSDirector Share Purchase
14th Dec 201612:15 pmRNSDirector Share Purchase
5th Dec 20167:00 amRNSInterim Results
5th Dec 20167:00 amRNSReports Positive Results in Phase II Stroke Trial
14th Nov 20167:00 amRNSNotification of Interim Results
5th Oct 20162:30 pmRNSNotification of Major Interest in Shares
22nd Sep 20161:00 pmRNSBlock Listing Review and Total Voting Rights
6th Sep 201612:00 pmRNSResult of AGM
6th Sep 20167:00 amRNSAGM Trading Update
5th Aug 20164:35 pmRNSPosting of Annual Report and Notice of AGM
4th Aug 20167:00 amRNSStroke clinical data published in The Lancet
22nd Jul 20167:00 amRNSPublication of positive pre-clinical retinal data
20th Jul 20162:31 pmRNSDirectors' Interest in Shares and Share Options
7th Jul 20167:00 amRNSPreliminary Results
14th Jun 20167:00 amRNSNotification of Preliminary Results
13th Jun 20167:00 amRNSPatient recruitment completed in stroke trial
9th Jun 20167:01 amRNSPursues brain cancer with exosome platform
8th Jun 20167:00 amRNSRetinitis pigmentosa update & Notice of KOL event
31st May 201612:45 pmRNSChange of Adviser
15th Mar 20167:00 amRNSFirst Patient Treated in RP Clinical Trial
23rd Feb 20167:00 amRNSReNeuron Relocates to South Wales
17th Feb 20164:57 pmRNSDirector's Dealings
3rd Feb 201610:07 amRNSDirector Share Purchase
1st Feb 20167:00 amRNSNotice of Grant of Key US Patent
12th Jan 20167:00 amRNSPre-clinical data relating to exosome platform
11th Jan 20167:00 amRNSWins UK grant to advance its exosome platform
17th Dec 20157:00 amRNSReNeuron establishes Scientific Advisory Board
7th Dec 20157:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.